$IMUC
EOM Pharmaceutical Holdings, Inc.

2018 Q2 Form 10-Q Financial Statement

#000082241118000007 Filed on May 14, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2018 Q1 2017 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $670.2K $734.6K $790.0K
YoY Change -32.18% -7.02% -28.18%
% of Gross Profit
Research & Development $58.98K $290.6K $4.686M
YoY Change -99.43% -93.8% -1.09%
% of Gross Profit
Depreciation & Amortization $100.00 $106.00 $16.60K
YoY Change -99.4% -99.36% -18.53%
% of Gross Profit
Operating Expenses $307.1K $1.025M $5.479M
YoY Change -97.29% -81.29% -6.14%
Operating Profit -$307.1K -$1.025M -$5.479M
YoY Change -97.29% -81.29% -6.14%
Interest Expense $0.00 $0.00 $452.7K
YoY Change -100.0% -100.0% 70.93%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$306.7K -$1.025M -$5.928M
YoY Change -92.43% -82.71% 5.23%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$306.7K -$1.025M -$5.928M
YoY Change -92.43% -82.71% 5.23%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$73.17K -$244.5K -$1.670M
COMMON SHARES
Basic Shares Outstanding 41.93M shares 41.93M shares 3.460M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q2 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.853M $5.027M $5.340M
YoY Change 57.25% -5.87% -69.5%
Cash & Equivalents $2.853M $5.027M $5.341M
Short-Term Investments
Other Short-Term Assets $489.7K $137.6K $494.2K
YoY Change -81.09% -72.15% -19.3%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $3.829M $5.164M $7.138M
YoY Change -13.04% -27.65% -63.3%
LONG-TERM ASSETS
Property, Plant & Equipment $356.00 $462.00 $93.23K
YoY Change -99.54% -99.5% -43.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.280M
YoY Change -35.43%
Total Long-Term Assets $356.00 $462.00 $3.369M
YoY Change -99.91% -99.99% -35.77%
TOTAL ASSETS
Total Short-Term Assets $3.829M $5.164M $7.138M
Total Long-Term Assets $356.00 $462.00 $3.369M
Total Assets $3.829M $5.165M $10.51M
YoY Change -20.4% -50.84% -57.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $84.26K $1.125M $914.6K
YoY Change -98.02% 22.99% -0.59%
Accrued Expenses $161.5K $215.0K $1.010M
YoY Change -95.06% -78.72% -11.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $401.9K $1.493M $2.159M
YoY Change -94.79% -30.83% -4.98%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.870M
YoY Change 33.62%
Total Long-Term Liabilities $0.00 $0.00 $7.870M
YoY Change -100.0% -100.0% 33.62%
TOTAL LIABILITIES
Total Short-Term Liabilities $401.9K $1.493M $2.159M
Total Long-Term Liabilities $0.00 $0.00 $7.870M
Total Liabilities $401.9K $1.493M $10.03M
YoY Change -94.81% -85.11% 22.85%
SHAREHOLDERS EQUITY
Retained Earnings -$117.8M -$117.5M -$102.0M
YoY Change 11.47% 15.11% 27.93%
Common Stock $121.2M $121.1M $102.5M
YoY Change 17.99% 18.15% 6.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.427M $3.672M $478.7K
YoY Change
Total Liabilities & Shareholders Equity $3.829M $5.165M $10.51M
YoY Change -20.4% -50.84% -57.45%

Cashflow Statement

Concept 2018 Q2 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$306.7K -$1.025M -$5.928M
YoY Change -92.43% -82.71% 5.23%
Depreciation, Depletion And Amortization $100.00 $106.00 $16.60K
YoY Change -99.4% -99.36% -18.53%
Cash From Operating Activities -$2.174M -$1.603M -$6.070M
YoY Change -37.04% -73.59% 13.45%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 $0.00 -$25.33K
YoY Change -100.0% -100.0% -109.57%
NET CHANGE
Cash From Operating Activities -2.174M -$1.603M -$6.070M
Cash From Investing Activities $0.00
Cash From Financing Activities 0.000 $0.00 -$25.33K
Net Change In Cash -2.174M -$1.603M -$6.096M
YoY Change -38.29% -73.7% 19.75%
FREE CASH FLOW
Cash From Operating Activities -$2.174M -$1.603M -$6.070M
Capital Expenditures $0.00
Free Cash Flow -$6.070M
YoY Change 13.36%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 dei Amendment Flag
AmendmentFlag
false
CY2018Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2018Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018Q1 dei Document Period End Date
DocumentPeriodEndDate
2018-03-31
CY2018Q1 dei Document Type
DocumentType
10-Q
CY2018Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000822411
CY2018Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
41928256 shares
CY2018Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2018Q1 dei Entity Registrant Name
EntityRegistrantName
ImmunoCellular Therapeutics, Ltd.
CY2018Q1 dei Trading Symbol
TradingSymbol
IMUC
CY2017Q1 imuc Change In Fair Value Of Warrant Liability For Income Taxes
ChangeInFairValueOfWarrantLiabilityForIncomeTaxes
-0.01
CY2018Q1 imuc Change In Fair Value Of Warrant Liability For Income Taxes
ChangeInFairValueOfWarrantLiabilityForIncomeTaxes
0.00
CY2017Q1 imuc Financing Costs Incurredbut Notyet Paid
FinancingCostsIncurredbutNotyetPaid
90881 USD
CY2018Q1 imuc Financing Costs Incurredbut Notyet Paid
FinancingCostsIncurredbutNotyetPaid
0 USD
CY2018Q1 imuc Working Capital
WorkingCapital
4147640 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1774626 USD
CY2018Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1124877 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
295612 USD
CY2018Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
214954 USD
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16339 USD
CY2018Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16445 USD
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
121087939 USD
CY2018Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
121135977 USD
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1727017 shares
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1727565 shares
CY2017Q4 us-gaap Assets
Assets
7009225 USD
CY2018Q1 us-gaap Assets
Assets
5164689 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
7008657 USD
CY2018Q1 us-gaap Assets Current
AssetsCurrent
5164227 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11437118 USD
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5341433 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6629870 USD
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5026602 USD
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6095685 USD
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1603268 USD
CY2017Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
466875 USD
CY2018Q1 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
467144 USD
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41913256 shares
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41913256 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41913256 shares
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41913256 shares
CY2018Q1 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
3393266 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
4191 USD
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
4191 USD
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2018Q1 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
851633 USD
CY2018Q1 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1138628 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2251184 USD
CY2018Q1 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2264634 USD
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3102817 USD
CY2018Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3403262 USD
CY2017Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0 USD
CY2018Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0 USD
CY2017Q1 us-gaap Depreciation
Depreciation
16595 USD
CY2018Q1 us-gaap Depreciation
Depreciation
106 USD
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.67
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2017Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2018Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2017Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2018Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017Q1 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.32
CY2018Q1 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.28
CY2017Q1 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.07
CY2018Q1 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.00
CY2017Q1 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.06
CY2018Q1 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.07
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
290516 USD
CY2018Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
153330 USD
CY2018Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P10M
CY2018Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
146382 USD
CY2018Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0 USD
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
793178 USD
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
734581 USD
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5927763 USD
CY2018Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1024981 USD
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2017Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2018Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-518434 USD
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-649749 USD
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
223184 USD
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-80658 USD
CY2017Q1 us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
-34620 USD
CY2018Q1 us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
0 USD
CY2017Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-875762 USD
CY2018Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-137186 USD
CY2017Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
452659 USD
CY2018Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0 USD
CY2017Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-297297 USD
CY2018Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-241162 USD
CY2017Q1 us-gaap Increase Decrease In Prepaid Supplies
IncreaseDecreaseInPrepaidSupplies
-55281 USD
CY2018Q1 us-gaap Increase Decrease In Prepaid Supplies
IncreaseDecreaseInPrepaidSupplies
0 USD
CY2017Q1 us-gaap Interest Expense
InterestExpense
452659 USD
CY2018Q1 us-gaap Interest Expense
InterestExpense
0 USD
CY2017Q1 us-gaap Interest Paid
InterestPaid
0 USD
CY2018Q1 us-gaap Interest Paid
InterestPaid
0 USD
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
3794 USD
CY2018Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
216 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7009225 USD
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5164689 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2360754 USD
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1493161 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-25328 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6070357 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1603268 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-5927763 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1024981 USD
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
5478898 USD
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
1025197 USD
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5478898 USD
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1025197 USD
CY2017Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
4000000 USD
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
378787 USD
CY2018Q1 us-gaap Other Assets Current
OtherAssetsCurrent
137625 USD
CY2017Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
25328 USD
CY2018Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
2 shares
CY2018Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
2 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16907 USD
CY2018Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16907 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
568 USD
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
462 USD
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4685720 USD
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
290616 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-116443659 USD
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-117468640 USD
CY2017Q1 us-gaap Revenues
Revenues
0 USD
CY2018Q1 us-gaap Revenues
Revenues
0 USD
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
171966 USD
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
48038 USD
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1250 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
91656 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
90406 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
42.31
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
41.65
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 USD
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
74637 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
46.38
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.00
CY2018Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
90.00
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.00
CY2018Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2017Q1 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1868607 USD
CY2018Q1 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
300445 USD
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3549514 shares
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41913256 shares
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y6M4D
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y2M5D
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2018Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
48038 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
4648471 USD
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
3671528 USD
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates </font><font style="font-family:inherit;font-size:10pt;">&#8211; The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions about the future outcome of current transactions, which may affect the reporting and disclosure of these transactions. Accordingly, actual results could differ from those estimates used in the preparation of these condensed consolidated financial statements.</font></div></div>

Files In Submission

Name View Source Status
0000822411-18-000007-index-headers.html Edgar Link pending
0000822411-18-000007-index.html Edgar Link pending
0000822411-18-000007.txt Edgar Link pending
0000822411-18-000007-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
imuc-20180331.xml Edgar Link completed
imuc-20180331.xsd Edgar Link pending
imuc-20180331_cal.xml Edgar Link unprocessable
imuc-20180331_def.xml Edgar Link unprocessable
imuc-20180331_lab.xml Edgar Link unprocessable
imuc-20180331_pre.xml Edgar Link unprocessable
imuc-33118x10q.htm Edgar Link pending
imuc-33118xexhibit311.htm Edgar Link pending
imuc-33118xexhibit312.htm Edgar Link pending
imuc-33118xexhibit321.htm Edgar Link pending
imuc-33118xexhibit322.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending